Oric Pharmaceuticals, Inc. (ORIC) Q3 2025 10-Q Quarterly Report
Oric Pharmaceuticals, Inc. (ORIC) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Oric Pharmaceuticals, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Market conditions risk of banking insolvency triggered by 2023 Silicon Valley Bank receivership causing temporary funds inaccessibility
- • Most material update: Net loss $99M for nine months ended Sept 30, 2025; accumulated deficit $661.7M, reflecting ongoing significant losses
- • Regulatory risk: FDA, EMA unpredictable approval processes; delays from Project Optimus dose optimization reform impacting oncology product candidates
- • Operational risk: Dependence on timely clinical trial completion and patient enrollment amid ongoing global pandemic disruptions affecting near-term progress
- • Financial risk: Cash $413M as of Sept 30, 2025, funding operations into second half of 2028, with potential capital needs earlier due to market uncertainties
Get deeper insights on Oric Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.